Shaping the future of heart health.
| Autor: | Cheng AYY, Zhang S, von Haehling S, Desai M |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Med (New York, N.Y.) [Med] 2024 Sep 13; Vol. 5 (9), pp. 1035-1037. |
| DOI: | 10.1016/j.medj.2024.08.002 |
| Abstrakt: | For World Heart Day on September 24, 2024, the World Heart Federation urges nations to endorse national strategies for enhancing cardiovascular health. While advancements show promise in reducing atherosclerosis, addressing healthcare inequalities and ensuring equitable access to tools remain crucial. This collection of voices touches on the intricate relationship between type 2 diabetes and cardiovascular disease, highlights innovative treatments for rare cardiomyopathies and heart failure, and explores the potentially transformative role of artificial intelligence in cardiovascular medicine, showcasing the dedication and innovation that are shaping the future of heart health. Competing Interests: Declaration of interests A.Y.Y.C. has served on advisory board of, has been a consultant for, and received honoraria for speaking from Abbott Diabetes, Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, GSK, HLS Therapeutics, Insulet, Janssen, Medtronic, Novo Nordisk, Pfizer, and Sanofi. S.Z. declares no conflicts of interest. S.v.H. has been a paid consultant for and/or received honoraria payments from AstraZeneca, Bayer, Boehringer Ingelheim, BRAHMS, Edwards Lifesciences, Novartis, Novo Nordisk, Pharmacosmos, Respicardia, and Vifor. S.v.H. reports research support from Amgen, AstraZeneca, Boehringer Ingelheim, Pharmacosmos, IMI, and the German Center for Cardiovascular Research (DZHK). M.D. is a consultant and has research agreements with Bristol Myers Squibb, Cytokinetics, Tenaya, Viz-AI, and Edgewise. (Copyright © 2024. Published by Elsevier Inc.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|